Comparing 3 approaches for hepatocellular carcinoma

Exclusion

• −Medical condition
• −Any evidence of uncontrolled intercurrent diseases
• −Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment
• −History of another primary malignancy
• −Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baselineBaselineYour starting measurements, taken before treatment begins.Read more →.
• −Clinically meaningful ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic controlControl groupThe group a new treatment is measured against.Read more → within 6 months prior to the first scheduled dose.
• −History of active primary immunodeficiency or active infection
• −History of hepatic encephalopathy
• −Current or recent (within 10 days of first dose of study treatment) use of aspirin (≥ 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol
• −Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purposes is ineligible
• −History of significant bleeding disorders, vasculitis, or a significant bleeding episode from the GI tract within 6 months prior to study randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more →.
• −Participants with untreated or incompletely treated varices with bleeding or high-risk (red wale signs or other high-risk factors) for bleeding.
• −HCC related
• −Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
• −Central nervous system metastases or spinal cord compression (including asymptomatic and adequately treated disease)
• −Prior treatment with anti-CTLA-4 and/or anti-TIGIT.
• −Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment